[PDF] Top 20 Rev. Bras. Reumatol. vol.53 número4 en v53n4a11
Has 10000 "Rev. Bras. Reumatol. vol.53 número4 en v53n4a11" found on our website. Below are the top 20 most common "Rev. Bras. Reumatol. vol.53 número4 en v53n4a11".
Rev. Bras. Reumatol. vol.53 número4 en v53n4a11
... None of the characteristics of the JIA, such as the sub- type of the disease or the presence of autoantibodies, identi- i ed a group with a higher risk for these changes, although the p[r] ... See full document
4
Rev. Bras. Reumatol. vol.53 número5 en v53n5a09
... The results of the systematic review and meta-analysis showed that patients who were treated with ADA 40 mg ev- ery two weeks associated with MTX showed better eficacy results and lowe[r] ... See full document
12
Rev. Bras. Reumatol. vol.53 número5 en v53n5a02
... shown more ischemic heart disease (prevalence ratio 1.2), pe- ripheral vascular disease (ratio 1.6), atherosclerosis (ratio 1.5), congestive heart failure (1.8) and more cardiovascular [r] ... See full document
5
Rev. Bras. Reumatol. vol.53 número5 en v53n5a03
... mains in FS cases, which were considered relevant by doctors and patients; and analyse the impact of the disease on the quality of life of patients. We also sought to identify the most[r] ... See full document
6
Rev. Bras. Reumatol. vol.53 número5 en v53n5a04
... The parameters assessed were: atlanto-axial subluxation, basilar invagination, erosion of the odontoid process of the axis, and subaxial instability.. Atlanto-axial subluxation was co[r] ... See full document
6
Rev. Bras. Reumatol. vol.53 número5 en v53n5a05
... the practice of physical exercises, as certain activities and modalities can cause joint pain in patients with osteoarthri- tis, and increase the risk of fractures in those with osteopo- rosis. In our study, we did not ... See full document
6
Rev. Bras. Reumatol. vol.53 número5 en v53n5a06
... To verify whether evidence of in vivo platelet hyperac- tivity would be reproduced in vitro, analysis of platelet ag- gregation curves with different agonists in the presence of aPL-ric[r] ... See full document
5
Rev. Bras. Reumatol. vol.53 número5 en v53n5a07
... In light of the issues mentioned above, the objectives of the current study were as follows: (1) to characterize the main symptoms of scleroderma and their impact on scleroderma patie[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número5 en v53n5a08
... Case 17, which demon- strated discrepant results in the CLIA (32 and 13.8 IU/mL), had been diagnosed with SLE and lupus nephritis 2 months prior, although anti-dsDNA results using both[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número5 en v53n5a10
... question was: What is the frequency of psychiatric comor- bidities in patients with SLE? Thus, the expected primary outcome is that psychiatric comorbidities are frequent and identiied[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número6 en v53n6a13
... The authors report a rare association case of juvenile idiopathic arthritis (JIA) and osteo- genesis imperfecta (OI) in a 53 years-old female patient, present a literature review and dis- cuss the radiological ... See full document
3
Rev. Bras. Reumatol. vol.53 número5 en v53n5a11
... sis, the vesiculobullous lesions that display distinct clinical and immunopathological features are described as bullous systemic lupus erythematosus (BSLE) and are part of the dif- fe[r] ... See full document
3
Rev. Bras. Reumatol. vol.53 número5 en v53n5a12
... We present a case of patient with ulcerative colitis, with positive c-ANCA, which progressed to hemoptysis associated with radiological i ndings consistent with pulmonary vasculitis.. [r] ... See full document
3
Rev. Bras. Reumatol. vol.53 número5 en v53n5a13
... inl iximab on the lipid proi le in a sample of patients with RA, psoriatic arthritis and SA, observed differences between the two agents, the i rst being associated with increases in T[r] ... See full document
4
Rev. Bras. Reumatol. vol.53 número5 en v53n5a14
... to demonstrate the safety of ustekinumab, Cuchacovich reported its use in patients who were refractory to photo- therapy, systemic corticosteroids and biologic therapy (in- cluding TNF [r] ... See full document
2
Rev. Bras. Reumatol. vol.53 número3 en v53n3a01
... Seven questions approach the use of biologic agents, especially anti-TNF drugs, as follows: their indication (Rec- ommendation 7); their efi cacy (Recommendation 8); their safety (Reco[r] ... See full document
2
Rev. Bras. Reumatol. vol.53 número3 en v53n3a05
... In the present study, although women with and without FM exhibited no differences regarding the level of total phys- ical activity and different types and intensities of activities per[r] ... See full document
6
Rev. Bras. Reumatol. vol.53 número3 en v53n3a07
... Introdução: O período de silêncio cutâneo (PSC) é um rel exo protetor inibitório da coluna vertebral e seus aferentes consistem em i bras nervosas A-delta. Nosso objetivo foi avaliar pacientes com i bromialgia ... See full document
8
Rev. Bras. Reumatol. vol.53 número3 en v53n3a08
... Fig. 1 – (A and B) MRI of thoracic spine on lateral view. Note the presence of a low signal lesion in T1 indicated by the arrows (A) before and (B) after contrast administration, with a homogeneous enhancement. (from: ... See full document
7
Rev. Bras. Reumatol. vol.53 número5 en v53n5a01
... what is now known as the Classii cation of Psoriatic Arthritis criteria (CASPAT).The original diagnostic criteria of Moll and Wright are now being replaced by the CASPAR criteria.. 3 [r] ... See full document
2
temas relacionados